This review (2020) examines the viability of microdosing psychedelics as a method to improve cognition and well-being. Available evidence indicates a variety of (perceived) benefits, including improvements in mood, focus, and creativity, with some people experiencing no discernible effects or expressing concerns about selective negative consequences like increased anxiety. However, most insights stem from observational studies using convenience samples that are biased or unrepresentative of the general population.
Abstract of The Viability of Microdosing Psychedelics as a Strategy to Enhance Cognition and Well-being
“Psychedelic substances are currently experiencing a renaissance in interest for both therapeutic as well as recreational applications. It has been proposed that microdosing, i.e., ingesting sub-perceptual doses of a psychedelic, could confer some of the benefits of these substances to users while minimizing the risks associated with full-dose use. This review aimed to summarize and examine the extant literature on psychedelic microdosing. Exploratory evidence published to date indicates a variety of benefits reported by microdosers including improvements in mood, focus, and creativity, with some null reports, and a minority of people reporting selective negative consequences such as increased anxiety and physiological discomfort. Methodological limitations of current evidence, however, make definitive conclusions hard to draw. Recommendations for future research are given.”
Author: Joel Bornemann
Summary of The Viability of Microdosing Psychedelics as a Strategy to Enhance Cognition and Well-being
This review begins by noting the recent resurgence of interest in psychedelic substances for both therapeutic and recreational purposes. While full doses of psychedelics have shown promise for treating various conditions and enhancing well-being, they can also lead to challenging experiences and, in rare cases, lasting psychological problems. Microdosing, which involves taking sub-perceptual doses of psychedelics (usually 1/10 to 1/20 of a typical dose), has been proposed as a way to access potential benefits while minimising risks.
The author aims to summarise the existing literature on psychedelic microdosing to investigate whether it can be a viable strategy for improving cognitive functioning and well-being, as well as to analyse any potential risks associated with the practice.
Methods
Find this paper
https://doi.org/10.1080/02791072.2020.1761573
Open Access | Google Scholar | Backup | 🕊
Cite this paper (APA)
Bornemann, J. (2020). The viability of microdosing psychedelics as a strategy to enhance cognition and well-being-an early review. Journal of Psychoactive Drugs, 52(4), 300-308.